Evidence map›Paper›PMID 37111584›Full record

ArticlePharmaceutics2023

Influence of Silver Nanoparticles on the Growth of Ascitic and Solid Ehrlich Adenocarcinoma: Focus on Copper Metabolism.

Daria N Magazenkova, Ekaterina A Skomorokhova, Mohammad Al Farroukh, Maria S Zharkova, Zena M Jassem, Valeria E Rekina, Olga V Shamova, Ludmila V Puchkova, Ekaterina Y Ilyechova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Some Properties of theInternational journal of molecular sciences · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Daria N MagazenkovaResearch Center of Advanced Functional Materials and Laser Communication Systems, Institute of Advanced Data Transfer Systems, ITMO University, 197101 St. Petersburg, Russia.ORCID 0000-0003-1959-7110
Ekaterina A SkomorokhovaDepartment of Molecular Genetics, Research Institute of Experimental Medicine, 197376 St. Petersburg, Russia.
Mohammad Al FarroukhFederal State Budgetary Scientific Institution, Saint Petersburg State University, 199034 St. Petersburg, Russia.ORCID 0000-0003-0017-4126
Maria S ZharkovaDepartment of General Pathology and Pathophysiology, Research Institute of Experimental Medicine, 197376 St. Petersburg, Russia.ORCID 0000-0003-3352-8197
Zena M JassemResearch Center of Advanced Functional Materials and Laser Communication Systems, Institute of Advanced Data Transfer Systems, ITMO University, 197101 St. Petersburg, Russia.
Valeria E RekinaInstitute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, 195251 St. Petersburg, Russia.
Olga V ShamovaDepartment of General Pathology and Pathophysiology, Research Institute of Experimental Medicine, 197376 St. Petersburg, Russia.ORCID 0000-0002-5168-2801
Ludmila V PuchkovaResearch Center of Advanced Functional Materials and Laser Communication Systems, Institute of Advanced Data Transfer Systems, ITMO University, 197101 St. Petersburg, Russia.ORCID 0000-0003-0958-2812
Ekaterina Y IlyechovaResearch Center of Advanced Functional Materials and Laser Communication Systems, Institute of Advanced Data Transfer Systems, ITMO University, 197101 St. Petersburg, Russia.ORCID 0000-0002-5623-2156
ITMO University · RUInstitute of Experimental Medicine · RUPeter the Great St. Petersburg Polytechnic University · RUSt Petersburg University · RU

Funding

Russian Science Foundation 20-74-10087
6 · The paper itself

Abstract

The link between copper metabolism and tumor progression motivated us to use copper chelators for suppression of tumor growth. We assume that silver nanoparticles (AgNPs) can be used for lowering bioavailable copper. Our assumption is based on the ability of Ag(I) ions released by AgNPs in biological media and interfere with Cu(I) transport. Intervention of Ag(I) into copper metabolism leads to the replacement of copper by silver in ceruloplasmin and the decrease in bioavailable copper in the bloodstream. To check this assumption, mice with ascitic or solid Ehrlich adenocarcinoma (EAC) were treated with AgNPs using different protocols. Copper status indexes (copper concentration, ceruloplasmin protein level, and oxidase activity) were monitored to assess copper metabolism. The expression of copper-related genes was determined by real-time PCR in the liver and tumors, and copper and silver levels were measured by FAAS. Intraperitoneal AgNPs treatment beginning on the day of tumor inoculation enhanced mice survival, reduced the proliferation of ascitic EAC cells, and suppressed the activity of HIF1α, TNF-α and VEGFa genes. Topical treatment by the AgNPs, which was started together with the implantation of EAC cells in the thigh, also enhanced mice survival, decreased tumor growth, and repressed genes responsible for neovascularization. The advantages of silver-induced copper deficiency over copper chelators are discussed.

Indexed as

copper-dependent regulatory factorscopper metabolismcopper statusEhrlich adenocarcinomasilver nanoparticlestumor growth

Identifiers

PMID37111584
PMCPMC10145613
OpenAlexW4361277870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.